{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:27:34Z","timestamp":1793946454329,"version":"4.8.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001823","name":"Ministry of Education Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","award":["CZ.02.01.01\/00\/22_008\/0004644"],"award-info":[{"award-number":["CZ.02.01.01\/00\/22_008\/0004644"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105503","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:53:43Z","timestamp":1785426823000},"page":"105503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploiting the weak link: Ataxia-Telangiectasia Mutated dysfunction in oesophagogastric tumours"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7874-2683","authenticated-orcid":false,"given":"Zuzanna","family":"Trybala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Costella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Bednarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Arcimowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radka Lordick","family":"Obermannov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2026.105503_bib1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.neo.2014.09.009","article-title":"Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts","volume":"16","author":"Abdel-Fatah","year":"2014","journal-title":"Neoplasia"},{"issue":"8\u20139","key":"10.1016\/j.critrevonc.2026.105503_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.dnarep.2004.04.002","article-title":"PI 3-kinase related kinases: \u2018Big\u2019 players in stress-induced signaling pathways","volume":"3","author":"Abraham","year":"2004","journal-title":"DNA Repair."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2199-8-29","article-title":"Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition","volume":"8","author":"Aguilar-Quesada","year":"2007","journal-title":"BMC Mol. Biol."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105503_bib4","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1111\/jcmm.17512","article-title":"Interaction between HER2 and ATM predicts poor survival in bladder cancer patients","volume":"26","author":"Albarakati","year":"2022","journal-title":"J. Cell. Mol. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105503_bib5","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3390\/biomedicines9081024","article-title":"Therapeutic potential of PARP inhibitors in the treatment of gastrointestinal cancers","volume":"9","author":"Alhusaini","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105503_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118137","article-title":"ATM inhibitors in cancer radiotherapy: mechanisms, clinical development, and future directions","volume":"300","author":"Al-Zoubi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105503_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11523-025-01136-6","article-title":"The development of ATM inhibitors in cancer therapy","volume":"20","author":"Ampolini","year":"2025","journal-title":"Target. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41698-025-01179-y","article-title":"Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer","volume":"9","author":"Arce-Gallego","year":"2025","journal-title":"NPJ Precis. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105503_bib9","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/15384101.2017.1312236","article-title":"Susceptibility of ATM-deficient pancreatic cancer cells to radiation","volume":"16","author":"Ayars","year":"2017","journal-title":"Cell. Cycle"},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105503_bib10","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2014.60.0320","article-title":"Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer","volume":"33","author":"Bang","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105503_bib11","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105503_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1700933","article-title":"Structures of closed and open conformations of dimeric human ATM","volume":"3","author":"Bareti\u0107","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105503_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug. Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105503_bib14","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/humu.21034","article-title":"Modeling ATM mutant proteins from missense changes confirms retained kinase activity","volume":"30","author":"Barone","year":"2009","journal-title":"Human. Mutat."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.critrevonc.2026.105503_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1068110","article-title":"Atypical ATMs: broadening the phenotypic spectrum of ATM-associated hereditary cancer","volume":"13","author":"Borja","year":"2023","journal-title":"Front. Oncol."},{"issue":"10_ement","key":"10.1016\/j.critrevonc.2026.105503_bib17","article-title":"Abstract A031: DNA-PK reenforces the S\/G2 checkpoint in ATM-deficient cells to limit ATR inhibitor efficacy","volume":"24","author":"Branigan","year":"2025","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0000000000000554","article-title":"PARP inhibitors in pancreatic cancer","volume":"27","author":"Brown","year":"2021","journal-title":"Cancer J."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105503_bib19","first-page":"264","article-title":"Interpreting and integrating genomic tests results in clinical cancer care: overview and practical guidance","volume":"74","author":"Casolino","year":"2024","journal-title":"CA A Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105503_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105503_bib21","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1038\/emboj.2009.294","article-title":"ATM activates p53 by regulating MDM2 oligomerization and E3 processivity","volume":"28","author":"Cheng","year":"2009","journal-title":"EMBO J."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105503_bib22","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/ijc.32228","article-title":"Bridging genomics and phenomics of gastric carcinoma","volume":"145","author":"Cho","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105503_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260089","article-title":"A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors","volume":"16","author":"Conroy","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib24","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1186\/s12885-022-10084-7","article-title":"ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer","volume":"22","author":"Davis","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11661-8","article-title":"ATM-deficiency increases genomic instability and metastatic potential in a mouse model of pancreatic cancer","volume":"7","author":"Drosos","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijrobp.2015.05.002","article-title":"Associations of ATM polymorphisms with survival in advanced esophageal squamous cell carcinoma patients receiving radiation therapy","volume":"93","author":"Du","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105503_bib27","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/s41416-020-1016-2","article-title":"Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models","volume":"123","author":"Dunlop","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13058-015-0575-2","article-title":"Low ATM protein expression in malignant tumor as well as cancer-associated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer","volume":"17","author":"Feng","year":"2015","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105503_bib29","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/sj.bjc.6601549","article-title":"Cellular responses to ionising radiation of AT heterozygotes: Differences between missense and truncating mutation carriers","volume":"90","author":"Fernet","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105503_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121364","article-title":"Survival in males with glioma and gastric adenocarcinoma correlates with mutant p53 residual transcriptional activity","volume":"3","author":"Fischer","year":"2018","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105503_bib31","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105503_bib32","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jnci\/djae098","article-title":"Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)","volume":"116","author":"Fontana","year":"2024","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semradonc.2021.09.008","article-title":"Targeting the ATM kinase to enhance the efficacy of radiotherapy and outcomes for cancer patients","volume":"32","author":"Garc\u00eda","year":"2022","journal-title":"Semin. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4161\/cc.11.6.19576","article-title":"Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control","volume":"11","author":"Golding","year":"2012","journal-title":"Cell. Cycle"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105503_bib35","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1078-0432.CCR-24-3936","article-title":"Reclassification of ATM missense variants of uncertain significance by integrating results from systematic functional assays into an ACMG points\u2013based framework","volume":"31","author":"Hanenberg","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105503_bib36","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105503_bib37","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/s41388-025-03343-x","article-title":"Dual inhibition of ATR and DNA-PKcs radiosensitizes ATM-mutant prostate cancer","volume":"44","author":"Hofstad","year":"2025","journal-title":"Oncogene"},{"issue":"39","key":"10.1016\/j.critrevonc.2026.105503_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciadv.adi8291","article-title":"Structural insights into the activation of ataxiatelangiectasia mutated by oxidative stress","volume":"9","author":"Howes","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105503_bib39","first-page":"1","article-title":"Assaying Radiosensitivity of Ataxia-Telangiectasia","volume":"1599","author":"Hu","year":"2017"},{"issue":"38","key":"10.1016\/j.critrevonc.2026.105503_bib40","doi-asserted-by":"crossref","first-page":"40953","DOI":"10.18632\/oncotarget.5944","article-title":"Prevalence of deleterious ATM germline mutations in gastric cancer patients","volume":"6","author":"Huang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105503_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155664","article-title":"Association of ATM and ARID1A in gastric carcinoma","volume":"263","author":"Hwang","year":"2024","journal-title":"Pathol. - Res. Pract."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105503_bib42","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jnci\/djac024","article-title":"ATM germline-mutated gastroesophageal junction adenocarcinomas: clinical descriptors, molecular characteristics, and potential therapeutic implications","volume":"114","author":"Jabbour","year":"2022","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105503_bib43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/ejhg.2011.196","article-title":"Underexpression and abnormal localization of ATM products in ataxia telangiectasia patients bearing ATM missense mutations","volume":"20","author":"Jacquemin","year":"2012","journal-title":"Eur. J. Human. Genet."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105503_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/cancers12030687","article-title":"ATM-deficient cancers provide new opportunities for precision oncology","volume":"12","author":"Jette","year":"2020","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105503_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.69","article-title":"ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)","volume":"6","author":"Jiang","year":"2016","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12943-024-01933-z","article-title":"The DNA damage sensor ATM kinase interacts with the p53 mRNA and guides the DNA damage response pathway","volume":"23","author":"Karakostis","year":"2024","journal-title":"Mol. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105503_bib47","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.3390\/cancers15164195","article-title":"Relevance of ATM status in driving sensitivity to DNA damage response inhibitors in patient-derived xenograft models","volume":"15","author":"Karmokar","year":"2023","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105503_bib48","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.3390\/ijms26167709","article-title":"ATR-CHK1 axis inhibitors in gastric cancer treatment","volume":"26","author":"Kciuk","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"44","key":"10.1016\/j.critrevonc.2026.105503_bib49","doi-asserted-by":"crossref","first-page":"31127","DOI":"10.1074\/jbc.274.44.31127","article-title":"Sensing of Ionizing Radiation-induced DNA Damage by ATM through Interaction with Histone Deacetylase","volume":"274","author":"Kim","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib50","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4143\/crt.2020.1247","article-title":"Increased radiosensitivity of solid tumors harboring ATM and BRCA1\/2 mutations","volume":"54","author":"Kim","year":"2022","journal-title":"Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.4132\/jptm.2016.08.08","article-title":"Immunohistochemistry for pathologists: protocols, pitfalls, and tips","volume":"50","author":"Kim","year":"2016","journal-title":"J. Pathol. Transl. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib52","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.21037\/jgo.2018.09.04","article-title":"Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy","volume":"9","author":"Klempner","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105503_bib53","article-title":"Exome sequencing points to pathogenic ATM variants in gastric cancer","author":"Koebbe","year":"2025","journal-title":"Eur. J. Human. Genet."},{"issue":"28","key":"10.1016\/j.critrevonc.2026.105503_bib54","doi-asserted-by":"crossref","first-page":"19817","DOI":"10.18632\/oncotarget.24865","article-title":"Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer","volume":"9","author":"Kondo","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105503_bib55","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0167-8140(98)00027-9","article-title":"Radiosensitivity and oxidative signalling in ataxia telangiectasia: an update","volume":"47","author":"Lavin","year":"1998","journal-title":"Radiother. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib56","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/sj.cdd.4401925","article-title":"The complexity of p53 stabilization and activation","volume":"13","author":"Lavin","year":"2006","journal-title":"Cell. Death & Differ."},{"issue":"8\u20139","key":"10.1016\/j.critrevonc.2026.105503_bib57","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.dnarep.2004.03.011","article-title":"Functional consequences of sequence alterations in the ATM gene","volume":"3","author":"Lavin","year":"2004","journal-title":"DNA Repair."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105503_bib58","doi-asserted-by":"crossref","first-page":"10434","DOI":"10.3390\/ijms231810434","article-title":"Quantitative correlations between radiosensitivity biomarkers show that the ATM protein kinase is strongly involved in the radiotoxicities observed after radiotherapy","volume":"23","author":"Le Reun","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105503_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102808","article-title":"Targeting the ATM pathway in cancer: opportunities, challenges and personalized therapeutic strategies","volume":"129","author":"Lee","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105503_bib60","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1053\/j.gastro.2023.07.015","article-title":"Germline determinants of esophageal adenocarcinoma","volume":"165","author":"Lee","year":"2023","journal-title":"Gastroenterology"},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105503_bib61","doi-asserted-by":"crossref","first-page":"10588","DOI":"10.1200\/JCO.2024.42.16_suppl.10588","article-title":"Impact of pathogenic germline variants in HRR genes on gastroesophageal cancer in a large real-world Chinese population: a comprehensive study","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105503_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21041214","article-title":"Mathematical model of atm activation and chromatin relaxation by ionizing radiation","volume":"21","author":"Li","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105503_bib63","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2017-314607","article-title":"Identification of distinct mutational patterns and new driver genes in oesophageal squamous cell carcinomas and adenocarcinomas","volume":"67","author":"Lin","year":"2018","journal-title":"Gut"},{"issue":"25","key":"10.1016\/j.critrevonc.2026.105503_bib64","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"issue":"7381","key":"10.1016\/j.critrevonc.2026.105503_bib65","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105503_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41431-026-02127-5","article-title":"Hereditary gastric cancer checks its balance at the ATM: Broadening risk beyond CDH1","author":"Lott","year":"2026","journal-title":"Eur. J. Human. Genet."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105503_bib67","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1083\/jcb.200908136","article-title":"ATR suppresses telomere fragility and recombination but is dispensable for elongation of short telomeres by telomerase","volume":"188","author":"McNees","year":"2010","journal-title":"J. Cell. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105503_bib68","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.semdp.2024.05.001","article-title":"Review of immunohistochemistry techniques: applications, current status, and future perspectives","volume":"41","author":"Mebratie","year":"2024","journal-title":"Semin. Diagn. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105503_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/PAI.0000000000000786","article-title":"Development of an immunohistochemical assay to detect the ataxia-telangiectasia mutated (ATM) protein in gastric carcinoma","volume":"28","author":"Miller","year":"2020","journal-title":"Appl. Immunohistochem. & Mol. Morphol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105503_bib70","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00208-7","article-title":"Profile of esophageal squamous cell carcinoma mutations in Brazilian patients","volume":"11","author":"Munari","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105503_bib72","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1128\/MCB.21.5.1828-1832.2001","article-title":"Early embryonic lethality in PARP-1 Atm double-mutant mice suggests a functional synergy in cell proliferation during development","volume":"21","author":"Murcia","year":"2001","journal-title":"Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105503_bib73","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","article-title":"Genomic instability\u2014an evolving hallmark of cancer","volume":"11","author":"Negrini","year":"2010","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105503_bib74","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.21037\/jtd.2019.12.25","article-title":"Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients","volume":"11","author":"Nong","year":"2019","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2026.105503_bib75","article-title":"Computational analysis of non-synonymous SNPs in ATM kinase: structural insights, functional implications, and inhibitor discovery","volume":"0123456789","author":"Panchal","year":"2024","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.critrevonc.2026.105503_bib76","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1146\/annurev-biochem-060614-034335","article-title":"Mechanisms of ATM activation","volume":"84","author":"Paull","year":"2015","journal-title":"Annu. Rev. Biochem."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105503_bib77","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.3390\/cancers13174259","article-title":"Targeting DNA damage repair mechanisms in pancreas cancer","volume":"13","author":"Perkhofer","year":"2021","journal-title":"Cancers"},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105503_bib78","doi-asserted-by":"crossref","first-page":"38326","DOI":"10.18632\/oncotarget.16215","article-title":"Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC","volume":"8","author":"Petersen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105503_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2026.101309","article-title":"Ataxia telangiectasia mutated (ATM) kinase as a predictive biomarker in clinical oncology: Implications for a precision treatment approach","volume":"77","author":"Pham","year":"2026","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/genes12060845","article-title":"Atm: Main features, signaling pathways, and its diverse roles in dna damage response, tumor suppression, and cancer development","volume":"12","author":"Phan","year":"2021","journal-title":"Genes"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105503_bib81","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/djaa095","article-title":"Pathogenic ATM mutations in cancer and a genetic basis for radiotherapeutic efficacy","volume":"113","author":"Pitter","year":"2021","journal-title":"JNCI Journal National Cancer Institute"},{"issue":"362","key":"10.1016\/j.critrevonc.2026.105503_bib82","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105503_bib83","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1158\/0008-5472.CAN-19-3126","article-title":"ATM loss confers greater sensitivity to ATR inhibition than PARP inhibition in prostate cancer","volume":"80","author":"Rafiei","year":"2020","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105503_bib84","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-0763","article-title":"Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation","volume":"68","author":"Rainey","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib85","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41598-019-39525-3","article-title":"Prognostic impact of ATM mutations in patients with metastatic colorectal cancer","volume":"9","author":"Randon","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105503_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell. Dev. Biol."},{"issue":"5218","key":"10.1016\/j.critrevonc.2026.105503_bib87","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1126\/science.7792600","article-title":"A single ataxia telangiectasia gene with a product similar to PI-3 kinase","volume":"268","author":"Savitsky","year":"1995","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105503_bib88","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1073\/pnas.012329699","article-title":"Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer","volume":"99","author":"Scott","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105503_bib89","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.06.010","article-title":"The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma","volume":"432","author":"Shi","year":"2018","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105503_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/genes12091370","article-title":"ATM\u2019s role in the repair of DNA double-strand breaks","volume":"12","author":"Shibata","year":"2021","journal-title":"Genes"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105503_bib91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrm3546","article-title":"The ATM protein kinase: regulating the cellular response to genotoxic stress, and more","volume":"14","author":"Shiloh","year":"2013","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105503_bib92","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010548","article-title":"The cold immunological landscape of ATM-deficient cancers","volume":"13","author":"Sinha","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105503_bib93","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S1470-2045(17)30719-2","article-title":"Missing a GOLDen opportunity in gastric cancer","volume":"18","author":"Smyth","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105503_bib94","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1086\/301706","article-title":"ATM mutations and phenotypes in Ataxia-Telangiectasia Families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer","volume":"62","author":"Stankovic","year":"1998","journal-title":"Am. J. Human. Genet."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105503_bib95","doi-asserted-by":"crossref","first-page":"28575","DOI":"10.18632\/oncotarget.15338","article-title":"Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer","volume":"8","author":"Stewart","year":"2017","journal-title":"Oncotarget"},{"issue":"32","key":"10.1016\/j.critrevonc.2026.105503_bib96","doi-asserted-by":"crossref","first-page":"30133","DOI":"10.1074\/jbc.M103160200","article-title":"Residual Ataxia Telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271T\u2192G mutations, showing a less severe phenotype","volume":"276","author":"Stewart","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105503_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153032","article-title":"ATM mutations as an independent prognostic factor and potential biomarker for immune checkpoint therapy in endometrial cancer","volume":"216","author":"Sun","year":"2020","journal-title":"Pathol. - Res. Pract."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105503_bib98","first-page":"280","article-title":"Ataxia Telangiectasia mutated protein loss and benefit from oxaliplatin-based chemotherapy in colorectal cancer","volume":"17","author":"Sundar","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105503_bib99","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf283","article-title":"PARP inhibitors in gastric cancer: unlocking precision oncology","volume":"30","author":"Tai","year":"2025","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib100","doi-asserted-by":"crossref","DOI":"10.1200\/PO.22.00085","article-title":"Utility of homologous recombination deficiency biomarkers across cancer types","author":"Takamatsu","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105503_bib101","doi-asserted-by":"crossref","first-page":"915","DOI":"10.20892\/j.issn.2095-3941.2023.0260","article-title":"Advances in ATM, ATR, WEE1, and CHK1\/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer","volume":"20","author":"Tang","year":"2023","journal-title":"Cancer Biol. Med."},{"issue":"5534","key":"10.1016\/j.critrevonc.2026.105503_bib102","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/258427a0","article-title":"Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity","volume":"258","author":"Taylor","year":"1975","journal-title":"Nature"},{"issue":"7517","key":"10.1016\/j.critrevonc.2026.105503_bib103","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"issue":"7636","key":"10.1016\/j.critrevonc.2026.105503_bib104","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","year":"2017","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105503_bib105","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41375-025-02615-5","article-title":"ATM aberrations in chronic lymphocytic leukemia: Del(11q) rather than ATM mutations is an adverse-prognostic biomarker","volume":"39","author":"Thorvaldsdottir","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105503_bib106","doi-asserted-by":"crossref","first-page":"699","DOI":"10.21037\/tlcr-23-853","article-title":"ATM\u2014the gene at the moment in non-small cell lung cancer","volume":"13","author":"Thu","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105503_bib107","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1158\/0008-5472.CAN-17-3103","article-title":"Deletion of Atm in tumor but not endothelial cells improves radiation response in a primary mouse model of lung adenocarcinoma","volume":"79","author":"Torok","year":"2019","journal-title":"Cancer Res."},{"issue":"8_Supplement_2","key":"10.1016\/j.critrevonc.2026.105503_bib108","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-CT267","article-title":"Abstract CT267: first results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors","volume":"85","author":"Ulahannan","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105503_bib109","series-title":"GeneReviews\u00ae. University of Washington, Seattle","article-title":"Ataxia-Telangiectasia","author":"Veenhuis","year":"1993"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105503_bib110","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1007\/s00432-022-04236-2","article-title":"SDC4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer risk","volume":"149","author":"Vuorinen","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"May","key":"10.1016\/j.critrevonc.2026.105503_bib111","first-page":"1","article-title":"Structure of the intact ATM\/Tel1 kinase","volume":"7","author":"Wang","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib112","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13046-021-02005-6","article-title":"PARP inhibitors in gastric cancer: beacon of hope","volume":"40","author":"Wang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105503_bib113","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74218","article-title":"Structure of the human ATM kinase and mechanism of Nbs1 binding","volume":"11","author":"Warren","year":"2022","journal-title":"eLife"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105503_bib114","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djy028","article-title":"The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers","volume":"110","author":"Weigelt","year":"2018","journal-title":"JNCI Journal National Cancer Institute"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105503_bib115","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf400","article-title":"NCI 10211: A phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer","volume":"30","author":"Wheless","year":"2025","journal-title":"Oncologist"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105503_bib116","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.3390\/cancers14153794","article-title":"DNA repair inhibitors potentiate fractionated radiotherapy more than single-dose radiotherapy in breast cancer cells","volume":"14","author":"Wong","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105503_bib117","article-title":"ATM is associated with the prognosis of colorectal cancer: A systematic review","volume":"15","author":"Wu","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105503_bib118","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.14709","article-title":"Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors","volume":"5","author":"Yamamoto","year":"2016","journal-title":"eLife"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib119","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","article-title":"Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results","volume":"29","author":"Yap","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib120","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-related (ATR) Inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105503_bib121","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3389\/fgene.2020.00933","article-title":"ATM mutations benefit bladder cancer patients treated with immune checkpoint inhibitors by acting on the tumor immune microenvironment","volume":"11","author":"Yi","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.critrevonc.2026.105503_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109661","article-title":"Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer","volume":"123","author":"Zheng","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105503_bib123","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.4251\/wjgo.v16.i5.2060","article-title":"Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor","volume":"16","author":"Zhou","year":"2024","journal-title":"World J. Gastrointest. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105503_bib124","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12967-025-06096-z","article-title":"Comprehensive genomic profiling of Chinese lung cancer characterizes germline-somatic mutation interactions influencing cancer risk","volume":"23","author":"Zhou","year":"2025","journal-title":"J. Transl. Med."},{"issue":"47","key":"10.1016\/j.critrevonc.2026.105503_bib125","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg2263","article-title":"ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer","volume":"9","author":"Zhou","year":"2023","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105503_bib126","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","article-title":"A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol. Cancer Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:40:48Z","timestamp":1793943648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":126,"alternative-id":["S1040842826003902"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105503","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting the weak link: Ataxia-Telangiectasia Mutated dysfunction in oesophagogastric tumours","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105503"}}